AI Article Synopsis

  • The study investigates how factors like genetics and clinical variability affect the pharmacokinetics of intravenous immunoglobulin (IVIG) treatment for immune disorders.
  • It involved analyzing blood samples and clinical data from 79 patients across four Malaysian hospitals, using advanced modeling techniques to estimate pharmacokinetic parameters.
  • The findings indicate that body weight is crucial for determining IVIG distribution and clearance, while the disease type also impacts how IVIG is distributed, but genetic variations in the FCGRT gene do not influence its pharmacokinetics.

Article Abstract

Purpose: Intravenous immunoglobulin (IVIG) is used to treat various immune system disorders, but the factors influencing its disposition are not well understood. This study aimed to estimate the population pharmacokinetic parameters of IVIG and to investigate the effect of genetic polymorphism of the FCGRT gene encoding the neonatal Fc receptor (FcRn) and clinical variability on the pharmacokinetic properties of IVIG in patients with immune system disorders.

Methods: Patients were recruited from 4 hospitals in Malaysia. Clinical data were recorded, and blood samples were taken for pharmacokinetic and genetic studies. Population pharmacokinetic parameters were estimated by nonlinear mixed-effects modeling in Monolix. Age, weight, baseline immunoglobulin G concentration, ethnicity, sex, genotype, disease type, and comorbidity were investigated as potential covariates. Models were evaluated using the difference in objective function value, goodness-of-fit plots, visual predictive checks, and bootstrap analysis.

Findings: A total of 292 blood samples were analyzed from 79 patients. The IVIG concentrations were best described by a 2-compartment model with linear elimination. Weight was found to be an important covariate for volume of distribution in the central compartment (Vc), volume of distribution in the peripheral compartment (Vp), and clearance in the central compartment, whereas disease type was found to be an important covariate for Vp. Goodness-of-fit plots indicated that the model fit the data adequately. Genetic polymorphism of the FCGRT gene encoding the neonatal Fc receptor did not affect the pharmacokinetic properties of IVIG.

Implications: This study supports the use of dosage based on weight as per current practice. The study findings highlight that Vp is significantly influenced by the type of disease being treated with IVIG. This relationship suggests that different disease types, particularly inflammatory and autoimmune conditions, may alter tissue permeability and fluid distribution due to varying degrees of inflammation. Increased inflammation can lead to enhanced permeability and retention of IVIG in peripheral tissues, reflecting higher Vp values.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2024.09.018DOI Listing

Publication Analysis

Top Keywords

population pharmacokinetic
12
immune system
12
intravenous immunoglobulin
8
system disorders
8
pharmacokinetic parameters
8
genetic polymorphism
8
polymorphism fcgrt
8
fcgrt gene
8
gene encoding
8
encoding neonatal
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!